137 related articles for article (PubMed ID: 34999555)
21. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients.
Komorowski AL; Hsu CC; Julka KD; Vasavada B; Lin CC; Wang CC; Chen CL
Neoplasma; 2018 Mar; 65(3):455-460. PubMed ID: 29788730
[TBL] [Abstract][Full Text] [Related]
22. AFP ratio predicts HCC recurrence after liver transplantation.
Koch C; Bette T; Waidmann O; Filmann N; Schrecker C; Trojan J; Weiler N; Vermehren J; Schnitzbauer AA; Bechstein WO; Zeuzem S; Herrmann E; Welker MW
PLoS One; 2020; 15(7):e0235576. PubMed ID: 32614912
[TBL] [Abstract][Full Text] [Related]
23. Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation.
Kornberg A; Witt U; Kornberg J; Friess H; Thrum K
Aliment Pharmacol Ther; 2015 Nov; 42(9):1101-10. PubMed ID: 26282466
[TBL] [Abstract][Full Text] [Related]
24. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
[TBL] [Abstract][Full Text] [Related]
25. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.
Piñero F; Tisi Baña M; de Ataide EC; Hoyos Duque S; Marciano S; Varón A; Anders M; Zerega A; Menéndez J; Zapata R; Muñoz L; Padilla Machaca M; Soza A; McCormack L; Poniachik J; Podestá LG; Gadano A; Boin IS; Duvoux C; Silva M;
Liver Int; 2016 Nov; 36(11):1657-1667. PubMed ID: 27169841
[TBL] [Abstract][Full Text] [Related]
26. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
27. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
28. Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort.
Maccali C; Chagas AL; Boin I; Quiñonez E; Marciano S; Vilatobá M; Varón A; Anders M; Hoyos Duque S; Lima AS; Menendez J; Padilla-Machaca M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Soza A; Fauda M; Perales SR; Vergara Sandoval R; Bermudez C; Beltran O; Arenas Hoyos I; McCormack L; Mattera FJ; Gadano A; Parente García JH; Tani CM; Augusto Carneiro D'Albuquerque L; Carrilho FJ; Silva M; Piñero F
Liver Int; 2021 Apr; 41(4):851-862. PubMed ID: 33217193
[TBL] [Abstract][Full Text] [Related]
29. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
[TBL] [Abstract][Full Text] [Related]
30. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
31. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
32. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
33. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.
Liu B; Teng F; Fu H; Guo WY; Shi XM; Ni ZJ; Gao XG; Ma J; Fu ZR; Ding GS
BMC Gastroenterol; 2015 Oct; 15():138. PubMed ID: 26472203
[TBL] [Abstract][Full Text] [Related]
34. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
36. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.
Al-Ameri AAM; Wei X; Liu P; Lin L; Shao Z; Xie H; Zhou L; Zheng S; Xu X
Ann Transplant; 2019 Aug; 24():489-498. PubMed ID: 31427563
[TBL] [Abstract][Full Text] [Related]
37. Mid-term outcome of percutaneous thermal ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation.
Shi Y; Chi J; Wang T; Cui D; Tang X; Ding M; Li P; Zhai B
Clin Radiol; 2019 Sep; 74(9):735.e1-735.e7. PubMed ID: 31307766
[TBL] [Abstract][Full Text] [Related]
38. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
[TBL] [Abstract][Full Text] [Related]
39. Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.
Chan KM; Wu TH; Cheng CH; Lee CF; Wu TJ; Chou HS; Lee WC
Biomed J; 2019 Oct; 42(5):335-342. PubMed ID: 31783994
[TBL] [Abstract][Full Text] [Related]
40. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation.
Donat M; Alonso S; Pereira F; Ferrero E; Carrión L; Acin-Gándara D; Moreno E
Transplant Proc; 2016; 48(6):1968-77. PubMed ID: 27569930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
